What's new? Log in Free sign up

Evaxion Biotech A/S (EVAX)

Company Profile

Company profile

Ticker

EVAX

Exchange

Website

www.evaxion-biotech.com

CEO

Christian Kanstrup

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Biological Products, (No Diagnostic Substances)

Silexion Therapeutics • Amgen • Gilead Sciences • Biogen • Qiagen • Sterling Check • Bio-Techne • Moderna • bluebird bio • Acorda Therapeutics ...

Former names

Evaxion Biotech A/S

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

EVAX stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Current report (foreign)

Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Current report (foreign)

Prospectus supplement for primary offering

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Registration statement (foreign)

Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1

Current report (foreign)

Evaxion announce 2026 financial calendar

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

ARMISTICE CAPITAL, LLC

ARMISTICE CAPITAL, LLC

Merck & Co., Inc.

ARMISTICE CAPITAL, LLC

Merck & Co., Inc.

Merck & Co., Inc.

Financial summary

Financial statements Chart EVAX financial data

Quarter (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2024

EVAX institutional ownership history Ownership history

12.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	9	9	–
Opened positions	2	5	-60.0%
Closed positions	2	0	NEW
Increased positions	1	1	–
Reduced positions	2	0	NEW

13F shares	Current	Prev Q	Change
Total value	681.50 mm	1.73 bn	-60.5%
Total shares	806.48 k	8.27 mm	-90.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
MRK Merck & Co.	542.28 k	$458.44 mm	-93.0%
Armistice Capital	150.46 k	$127.20 mm	-68.8%
Invst	50.40 k	$42.61 mm	+16.7%
Catalina Capital	34.86 k	$29.47 mm	NEW
Millennium Management	22.54 k	$18.77 mm	NEW
Beacon Capital Management	4.86 k	$4.11 mm	0.0%
JPM JPMorgan Chase & Co.	780.00	$650.00 k	0.0%
Rhumbline Advisers	290.00	$240.00 k	0.0%
SSB SouthState	4.00	$3.00 k	0.0%
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
MRK Merck & Co.	542.28 k	-7.18 mm	-93.0%
Armistice Capital	150.46 k	-332.54 k	-68.8%
Catalina Capital	34.86 k	+34.86 k	NEW
Millennium Management	22.54 k	+22.54 k	NEW
Citadel Advisors	0.00	-14.83 k	EXIT
Invst	50.40 k	+7.20 k	+16.7%
BLK BlackRock	0.00	-1.51 k	EXIT
JPM JPMorgan Chase & Co.	780.00	0.00	0.0%
Proequities	0.00	0.00
SSB SouthState	4.00	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.

Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses

Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens

Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce viral infection in preclinical models EVX-V1 is a next-generation, multi-component vaccine program combining these

Evaxion Announces New Data Exploring Immune Responses Following Treatment With AI-designed Personalized Cancer Vaccine EVX-01

Earnings Scheduled For November 6, 2025

Press releases

From Benzinga Pro

Sidoti Events, LLC's Year-End Virtual Investor Conference

NEW YORK, NY / ACCESS Newswire / December 9, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day Year-End Virtual Investor Conference

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted immune responses

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.